科倫藥業(002422.SZ)放量大跌7%為連續第五日下跌
格隆匯8月20日丨繼近日連續4個交易日收跌後,科倫藥業(002422.SZ)今日再度大跌,現報28.44元,跌7.21%,創7月15日以來新低,暫成交11.21億元,今日下跌過程中成交額逐步放大,最新總市值409億元。該股曾於8月14日創出階段新高33.5元后一路下跌至今,5日期間的最大跌幅達15.5%。8月16日,科倫藥業公開配股獲得中國證監會受理。公司曾於7月初公佈配股預案,採用向原股東配售股份方式實行,按照每10股配售不超過1.4股的比例向全體股東配售。公司控股股東、實際控制人已出具承諾以現金方式全額認購其可配售的股份。有數據顯示,7月26日,董事劉革新的相關人(兄弟姐妹)劉綏華通過競價交易方式減持股份172.39萬股,成交均價為31.92元。此外,公司將於8月28日公佈財報。(行情來源:富途證券)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.